Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093335 | 0.86 | KMT2A (0.59) | HRH3KMT2AALDH1A1MEN1ATM | |
| SCHEMBL13375736 | 0.85 | KMT2A (0.62) | KMT2AALDH1A1MEN1ATMCHRNA1 | |
| SCHEMBL1976999 | 0.84 | KMT2A (0.61) | HRH3KMT2AALDH1A1MEN1ATM | |
| SCHEMBL13374354 | 0.84 | KMT2A (0.57) | HRH3KMT2AALDH1A1MEN1ATM | |
| SCHEMBL17828165 | 0.83 | HRH3 (0.60) | HRH3KMT2AALDH1A1ACHE | |
| SCHEMBL27620106 | 0.82 | ALDH1A1 (0.58) | HRH3KMT2AALDH1A1MEN1ATM | |
| SCHEMBL5048083 | 0.82 | KMT2A (0.63) | HRH3KMT2AALDH1A1MEN1ATM | |
| SCHEMBL1823298 | 0.82 | KMT2A (0.63) | HRH3KMT2AALDH1A1MEN1ATM | |
| SCHEMBL2231495 | 0.81 | HRH3 (0.58) | HRH3KMT2AALDH1A1ACHE | |
| SCHEMBL2231491 | 0.81 | HRH3 (0.58) | HRH3KMT2AALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | claimed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | claimed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| CN-100519550-C | 2-oxoindole compounds having inhibitory activity on glycogen synthase kinase 3 receptor | ASTRAZENECA AB SE (SE) | 2009-07-29 | — | — | CN | disclosed |
| CN-101296906-A | (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943231-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| WO-2007048802-A1 | (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | disclosed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | HRH3 89/4885KMT2A 474/4885ALDH1A1 3960/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | HRH3 387/4885KMT2A 3976/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.